[
  {
    "ts": null,
    "headline": "Eli Lilly Wins Fresh Bullish Call From BMO",
    "summary": "$840 target backed by optimism on new obesity drug",
    "url": "https://finnhub.io/api/news?id=52cbee5b220b94fbddd2f96445d7a670ffe429d282e0142e4dd397afe55530ad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756939920,
      "headline": "Eli Lilly Wins Fresh Bullish Call From BMO",
      "id": 136641778,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "$840 target backed by optimism on new obesity drug",
      "url": "https://finnhub.io/api/news?id=52cbee5b220b94fbddd2f96445d7a670ffe429d282e0142e4dd397afe55530ad"
    }
  },
  {
    "ts": null,
    "headline": "Factbox-Global drugmakers rush to boost US presence as tariff threat looms",
    "summary": "But with many countries still engaged in trade talks with the U.S., businesses around the world are hedging their decisions pending more clarity on final tariff rates.  The U.S. drugmaker plans to invest $27 billion to build four new manufacturing facilities over the next five years in the U.S. It aims to announce two of its new site locations this quarter.  The drugmaker plans to raise U.S. investments by 25%, totaling $55 billion, over the next four years.",
    "url": "https://finnhub.io/api/news?id=35abbd617332d141878bb80b64dd0dff91b88df1fc45fda598bd74021d9a119e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756926558,
      "headline": "Factbox-Global drugmakers rush to boost US presence as tariff threat looms",
      "id": 136631118,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "But with many countries still engaged in trade talks with the U.S., businesses around the world are hedging their decisions pending more clarity on final tariff rates.  The U.S. drugmaker plans to invest $27 billion to build four new manufacturing facilities over the next five years in the U.S. It aims to announce two of its new site locations this quarter.  The drugmaker plans to raise U.S. investments by 25%, totaling $55 billion, over the next four years.",
      "url": "https://finnhub.io/api/news?id=35abbd617332d141878bb80b64dd0dff91b88df1fc45fda598bd74021d9a119e"
    }
  },
  {
    "ts": null,
    "headline": "The Problem With Weight Loss Stocks",
    "summary": "There are new ways to tackle weight loss, but the stocks leading the way are lagging.",
    "url": "https://finnhub.io/api/news?id=ccbc1daa7b31533fea3632007c13c51ba380e0b85ab1192159d67a0c6b07af4e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756925280,
      "headline": "The Problem With Weight Loss Stocks",
      "id": 136631119,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "There are new ways to tackle weight loss, but the stocks leading the way are lagging.",
      "url": "https://finnhub.io/api/news?id=ccbc1daa7b31533fea3632007c13c51ba380e0b85ab1192159d67a0c6b07af4e"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers gains after court rejects Eli Lilly’s case against Willow",
    "summary": "Investing.com -- Shares of Hims Hers Health Inc (NYSE:HIMS) jumped 8.2% Wednesday after a key legal development eased market concerns about potential litigation from major pharmaceutical companies. A federal judge’s dismissal of Eli Lilly’s (NYSE:LLY) lawsuit against Willow Health, a telehealth provider similar to Hims, was seen as a meaningful rebuke of efforts to stifle compounded versions of branded weight-loss drugs.",
    "url": "https://finnhub.io/api/news?id=f32345b987875b719ebd72e1f4e25c848ef1f262421d16e368e3a4d42c9e5dd6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756923592,
      "headline": "Hims & Hers gains after court rejects Eli Lilly’s case against Willow",
      "id": 136631120,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- Shares of Hims Hers Health Inc (NYSE:HIMS) jumped 8.2% Wednesday after a key legal development eased market concerns about potential litigation from major pharmaceutical companies. A federal judge’s dismissal of Eli Lilly’s (NYSE:LLY) lawsuit against Willow Health, a telehealth provider similar to Hims, was seen as a meaningful rebuke of efforts to stifle compounded versions of branded weight-loss drugs.",
      "url": "https://finnhub.io/api/news?id=f32345b987875b719ebd72e1f4e25c848ef1f262421d16e368e3a4d42c9e5dd6"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Urges Patience With Eli Lilly and Company (LLY)’s Stock",
    "summary": "We recently published 9 Stocks On Jim Cramer’s Radar . Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed. Weight loss drug giant Eli Lilly and Company (NYSE:LLY)’s shares have lost 5.9% year-to-date as investors have questioned the firm’s weight loss drug trials. Cramer has been a fan of the firm […]",
    "url": "https://finnhub.io/api/news?id=54753dea1e74f79cb526770f02364ab66664316347d25b9f48f126e31ea4b5b1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756919539,
      "headline": "Jim Cramer Urges Patience With Eli Lilly and Company (LLY)’s Stock",
      "id": 136616892,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published 9 Stocks On Jim Cramer’s Radar . Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed. Weight loss drug giant Eli Lilly and Company (NYSE:LLY)’s shares have lost 5.9% year-to-date as investors have questioned the firm’s weight loss drug trials. Cramer has been a fan of the firm […]",
      "url": "https://finnhub.io/api/news?id=54753dea1e74f79cb526770f02364ab66664316347d25b9f48f126e31ea4b5b1"
    }
  },
  {
    "ts": null,
    "headline": "Insider Watch: 3 CEOs Buying the Dip",
    "summary": "Large-cap stocks CHD, LLY, and VTRS have seen their respective CEOs make purchases over the last month. What do they see?",
    "url": "https://finnhub.io/api/news?id=1d15d39a5f8e33d802348c209c810385420a5f397c97ea8875d76670af93c85c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756917000,
      "headline": "Insider Watch: 3 CEOs Buying the Dip",
      "id": 136616893,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Large-cap stocks CHD, LLY, and VTRS have seen their respective CEOs make purchases over the last month. What do they see?",
      "url": "https://finnhub.io/api/news?id=1d15d39a5f8e33d802348c209c810385420a5f397c97ea8875d76670af93c85c"
    }
  },
  {
    "ts": null,
    "headline": "Defiance Launches LLYZ: The First 2X Short ETF for Eli Lilly",
    "summary": "Defiance Launches LLYZ: The First 2X Short ETF for Eli Lilly Defiance ETFs, a leader in thematic and leveraged exchange-traded funds, today announced the launch of the Defiance Daily Target 2X Short LLY ETF (Ticker: LLYZ). This fund provides investors with amplified 2X inverse daily exposure to the performance of Eli Lilly and Company (NYSE: LLY), enabling retail investors to seek enhanced downside exposure without the need for a margin account. MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Defiance",
    "url": "https://finnhub.io/api/news?id=ea537cbc7ab1384159714306543eb90145b0c5eafad9469588981541d383dd86",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756909800,
      "headline": "Defiance Launches LLYZ: The First 2X Short ETF for Eli Lilly",
      "id": 136615671,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Defiance Launches LLYZ: The First 2X Short ETF for Eli Lilly Defiance ETFs, a leader in thematic and leveraged exchange-traded funds, today announced the launch of the Defiance Daily Target 2X Short LLY ETF (Ticker: LLYZ). This fund provides investors with amplified 2X inverse daily exposure to the performance of Eli Lilly and Company (NYSE: LLY), enabling retail investors to seek enhanced downside exposure without the need for a margin account. MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Defiance",
      "url": "https://finnhub.io/api/news?id=ea537cbc7ab1384159714306543eb90145b0c5eafad9469588981541d383dd86"
    }
  },
  {
    "ts": null,
    "headline": "Lung Disease Breakthrough Boosts United Therapeutics — and its Rivals",
    "summary": "About 5 million people are affected by idiopathic pulmonary fibrosis globally, according to the National Institutes of Health.",
    "url": "https://finnhub.io/api/news?id=988c1d0aa20bb4742ea7701e36a39f25b5940fa676fd1429aadacf7cc7ca3f4f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756899000,
      "headline": "Lung Disease Breakthrough Boosts United Therapeutics — and its Rivals",
      "id": 136631121,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "About 5 million people are affected by idiopathic pulmonary fibrosis globally, according to the National Institutes of Health.",
      "url": "https://finnhub.io/api/news?id=988c1d0aa20bb4742ea7701e36a39f25b5940fa676fd1429aadacf7cc7ca3f4f"
    }
  },
  {
    "ts": null,
    "headline": "Zacks Investment Ideas feature highlights: Eli Lilly, Eaton and Interactive Brokers",
    "summary": "Eli Lilly, Eaton, and Interactive Brokers post standout Q2 results, with booming sales, raised guidance, and record-breaking growth.",
    "url": "https://finnhub.io/api/news?id=72666689f17c0a09018317f0fd404a86df04cd68b116916a6e85fb4707fb7dc9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756889700,
      "headline": "Zacks Investment Ideas feature highlights: Eli Lilly, Eaton and Interactive Brokers",
      "id": 136612871,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly, Eaton, and Interactive Brokers post standout Q2 results, with booming sales, raised guidance, and record-breaking growth.",
      "url": "https://finnhub.io/api/news?id=72666689f17c0a09018317f0fd404a86df04cd68b116916a6e85fb4707fb7dc9"
    }
  }
]